FIELD: biotechnology.
SUBSTANCE: following is provided: a pharmaceutical composition for use in the treatment of an interleukin 18 (IL-18)-associated disease or disorder in an individual suffering from such disease or disorder. Also the following is provided: the methods of treating an IL-18-associated disease or disorder in an individual, wherein the individual is one of a group of patients having abnormal levels of free IL-18 that exceed the level of free IL-18 in the body fluid of a healthy individual.
EFFECT: invention provides effective treatment of IL-18-associated diseases.
57 cl, 12 dwg, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IL-18-BINDING PROTEIN (IL-18BP) AND ANTIBODIES IN INFLAMMATORY DISEASES | 2016 |
|
RU2755691C2 |
| USE OF IL-18-BINDING PROTEIN (IL-18BP) IN INFLAMMATORY DISEASES | 2014 |
|
RU2731713C2 |
| ANTI-IL-5 ANTIBODIES | 2017 |
|
RU2758008C2 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| PEPTIDE VACCINES AGAINST INTERLEUKIN-31 | 2019 |
|
RU2786441C2 |
| GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF | 2018 |
|
RU2820628C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
